WIBICAL®
Bicalutamide
Bicalutamide is a non-steroidal antiandrogen, lacking other endocrine activity. It binds to androgen receptors without activating gene expression and thus inhibits androgen stimulation, causing inhibition of prostate tumor regression. WIBICAL® is available in two different strengths (50 mg and 150 mg) and in blister packs of 30 capsules. WIBICAL® (50mg) is mainly indicated for the treatment of advanced prostate cancer in combination with hormonal therapy (LHRH agonists) or surgical castration. WIBICAL® (150mg) is indicated, either alone or as an adjunct to radical prostatectomy or radiotherapy, in patients with locally advanced prostate cancer at high risk of disease progression.
Sincerely Pharmaceutical Tech
Regards,
Client Success Team (CRM),
Please fill the all required fields....!!
Sincerely Packaging Labelling